Analyst Price Target is $1,240.00
▲ +4,000.53% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Smith & Nephew in the last 3 months. The average price target is $1,240.00, with a high forecast of $1,480.00 and a low forecast of $1,000.00. The average price target represents a 4,000.53% upside from the last price of $30.24.
Current Consensus is
The current consensus among 9 polled investment analysts is to hold stock in Smith & Nephew. This rating has held steady since July 2021, when it changed from a Buy consensus rating.
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.